Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Liabilities: 2022-2024

Historic Total Liabilities for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $511.5 million.

  • Axsome Therapeutics' Total Liabilities rose 27.10% to $595.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 27.10%. This contributed to the annual value of $511.5 million for FY2024, which is 28.75% up from last year.
  • As of FY2024, Axsome Therapeutics' Total Liabilities stood at $511.5 million, which was up 28.75% from $397.3 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Total Liabilities ranged from a high of $511.5 million in FY2024 and a low of $221.9 million during FY2022.
  • Its 3-year average for Total Liabilities is $376.9 million, with a median of $397.3 million in 2023.
  • Data for Axsome Therapeutics' Total Liabilities shows a peak YoY spiked of 79.01% (in 2023) over the last 5 years.
  • Over the past 3 years, Axsome Therapeutics' Total Liabilities (Yearly) stood at $221.9 million in 2022, then surged by 79.01% to $397.3 million in 2023, then rose by 28.75% to $511.5 million in 2024.